Aptevo Therapeutics Inc. Contracts & Agreements
85 Contracts & Agreements
- Business Finance (46 contracts)
- Business Operations (11)
- Human Resources (10)
- Intellectual Property (5)
- Real Estate (3)
- Uncategorized (10)
- Securities Purchase Agreement, dated April 10, 2024, between the Company and the purchasers party thereto (Filed With SEC on April 15, 2024)
- Placement Agent Agreement, dated April 10, 2024, between the Company and Roth Capital Partners (Filed With SEC on April 15, 2024)
- Pre-funded Warrant, dated April 15, 2024 (Filed With SEC on April 15, 2024)
- Common Warrant, dated April 15, 2024 (Filed With SEC on April 15, 2024)
- Form of Placement Agency Agreement (Filed With SEC on March 20, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on March 20, 2024)
- Form of Common Warrant (Filed With SEC on March 20, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on March 20, 2024)
- Form of New Series A-1 Warrant (Filed With SEC on November 9, 2023)
- Form of New Series A-2 Warrant (Filed With SEC on November 9, 2023)
- Form of New Series B-1 Warrant (Filed With SEC on November 9, 2023)
- Form of New Series B-2 Warrant (Filed With SEC on November 9, 2023)
- Form of Warrant Inducement Agreement, by and between the Company and each Holder (Filed With SEC on November 9, 2023)
- Financial Advisory Agreement, dated as of November 9, 2023, between A.G.P./Alliance Global Partners and the Company (Filed With SEC on November 9, 2023)
- Amendment No. 3 to Rights Agreement, dated as of November 2, 2023, between the Company and Broadridge Corporate Issuer Solution, Inc., as Rights Agent (Filed With SEC on November 3, 2023)
- Series A Common Warrant, dated August 4, 2023 (Filed With SEC on August 7, 2023)
- Series B Common Warrant, dated August 4, 2023 (Filed With SEC on August 7, 2023)
- Pre-funded Warrant, dated August 4, 2023 (Filed With SEC on August 7, 2023)
- Placement Agent Agreement, dated August 1, 2023, between the Company and A.G.P./Alliance Global Partners (Filed With SEC on August 7, 2023)
- Securities Purchase Agreement, dated August 1, 2023, between the Company and the purchasers party thereto (Filed With SEC on August 7, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on July 14, 2023)
- Form of Common Warrant (Filed With SEC on July 14, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on July 14, 2023)
- Form of Placement Agent Agreement (Filed With SEC on July 14, 2023)
- Third Amendment to Credit and Security Agreement dated August 30, 2022 (Filed With SEC on November 10, 2022)
- Amendment No. 2 to Rights Agreement, dated as of November 4, 2022, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent (Filed With SEC on November 4, 2022)
- Amendment to Royalty Purchase Agreement dated June 7, 2022 (Filed With SEC on August 11, 2022)
- Limited Consent and Second Amendment to Credit and Security Agreement dated June 7, 2022 (Filed With SEC on August 11, 2022)
- Ninth Amendment to Office Lease, dated May 26, 2022, by and between Aptevo Therapeutics Inc. and Selig Real Estate Holdings Eight L.L.C (Filed With SEC on August 11, 2022)
- Agreement to Terminate Registration Rights Agreement between the Company and Intervac L.L.C. and BioVac L.L.C (Filed With SEC on March 24, 2022)
- Aptevo Therapeutics Inc. Amended and Restated Senior Management Severance Plan (Filed With SEC on March 24, 2022)
- Registration Rights Agreement, dated February 16, 2022, by and between the Company and Lincoln Park (Filed With SEC on February 17, 2022)
- Purchase Agreement, dated February 16, 2022, by and between the Company and Lincoln Park (Filed With SEC on February 17, 2022)
- Amendment to Executive Transition Services Agreement (Filed With SEC on November 12, 2021)
- Executive Transition Services Agreement (Filed With SEC on November 12, 2021)
- Amendment No. 1 to Rights Agreement, dated as of November 5, 2021, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent (Filed With SEC on November 5, 2021)
- Royalty Purchase Agreement by and among Aptevo Therapeutics Inc. and Healthcare Royalty Partners IV, LP. dated as of March 30, 2021 (Filed With SEC on May 11, 2021)
- Description of Capital Stock of Aptevo Therapeutics (Filed With SEC on March 31, 2021)
- Equity Distribution Agreement, dated December 14, 2020, between Aptevo Therapeutics Inc. and Piper Sandler & Co (Filed With SEC on December 14, 2020)
- Rights Agreement, dated as of November 8, 2020, by and between Aptevo Therapeutics Inc. and Broadridge Corporate Issuer Solutions, Inc., as rights agent (Filed With SEC on November 9, 2020)
- Amendment No. 4 to the Collaboration and License Agreement dated as of December 19, 2005 (as previously amended, the Agreement) by and between Emergent Product Development... (Filed With SEC on August 14, 2020)
- Amendment No. 3 to the Collaboration and License Agreement dated as of December 19, 2005 (as previously amended, the Agreement) by and between Emergent Product Development... (Filed With SEC on August 14, 2020)
- Amendment No. 2 to the Collaboration and License Agreement dated as of December 19, 2005 (as previously amended, the Agreement) by and between Trubion Pharmaceuticals, Inc.... (Filed With SEC on August 14, 2020)
- Amendment No. 1 to the Collaboration and License Agreement dated as of December 19, 2005 (the Agreement) by and between Trubion Pharmaceuticals, Inc. (Trubion) and Wyeth, acting... (Filed With SEC on August 14, 2020)
- Collaboration and License Agreement, dated as of December 19, 2005, by and among Wyeth Pharmaceuticals and Trubion Pharmaceuticals, Inc (Filed With SEC on August 14, 2020)
- LLC Purchase Agreement by and among Aptevo Therapeutics Inc. and Medexus Pharma, Inc. dated February 28, 2020 (Filed With SEC on March 2, 2020)
- Amendment to Lease Dated April 28, 2003 by and between Selig Real Estate Holdings Eight, LLC and later assigned to SREH 2018 Holdings LLC and Aptevo Research and Development LLC (Filed With SEC on November 7, 2019)
- Amendment to LLC Purchase Agreement, dated as of August 31, 2017, by and among Aptevo BioTherapeutics LLC, Aptevo Therapeutics Inc., Venus Bio Therapeutics Sub LLC, and Saol... (Filed With SEC on August 9, 2019)
- Eighth Amendment to Office Lease, dated as of March 19, 2019, by and between Aptevo Therapeutics Inc. and Selig Real Estate Holdings Eight L.L.C (Filed With SEC on March 22, 2019)
- Intellectual Property Security Agreement, dated February 7, 2019, by and amoung, Aptevo Therapeutics Inc., Aptevo Biotherapeutics LLC., Aptevo Research and Development, LLC and... (Filed With SEC on March 18, 2019)
- Amendment No. 1 to Amended and Restated Credit and Security Agreement, dated December 14, 2018, by and among, Aptevo Therapeutics Inc., Aptevo Biotherapeutics LLC, Aptevo Research... (Filed With SEC on March 18, 2019)
- Form of Warrant (Filed With SEC on March 11, 2019)
- Form of Pre-Funded Warrant (Filed With SEC on March 11, 2019)
- Underwriting Agreement between Aptevo Therapeutics, Inc. and Piper Jaffray & Co., dated March 7, 2019 (Filed With SEC on March 11, 2019)
- Registration Rights Agreement between Aptevo Therapeutics Inc. and Lincoln Park Capital Fund, LLC, dated December 20, 2018 (Filed With SEC on December 24, 2018)
- Purchase Agreement between Aptevo Therapeutics Inc. and Lincoln Park Capital Fund, LLC, dated December 20, 2018 (Filed With SEC on December 24, 2018)
- Aptevo Therapeutics Inc. Non-Statutory Stock Option Agreement (Filed With SEC on August 9, 2018)
- Aptevo Therapeutics Inc. 2018 Stock Incentive Plan (Filed With SEC on August 9, 2018)
- Amendment No. 3 to Credit and Security Agreement, dated as of February 23, 2018, by and among Aptevo Therapeutics Inc. and certain of its subsidiaries and Midcap Financial Trust (Filed With SEC on March 13, 2018)
- Amended and Restated Trademark License Agreement, dated September 28, 2017, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc (Filed With SEC on March 13, 2018)
- Amended and Restated Manufacturing Services Agreement, dated September 28, 2017, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc (Filed With SEC on March 13, 2018)
- LLC Purchase Agreement, dated as of August 31, 2017, by and among Aptevo BioTherapeutics LLC, Aptevo Therapeutics Inc., Venus Bio Therapeutics Sub LLC, and Saol International... (Filed With SEC on November 13, 2017)
- Collaboration and Option Agreement, dated as of July 20, 2017, by and between Aptevo Research and Development LLC, and Alligator Bioscience AB (Filed With SEC on November 13, 2017)
- Equity Distribution Agreement, dated November 9, 2017, between Aptevo Therapeutics Inc. and Piper Jaffray and Company, LLC (Filed With SEC on November 9, 2017)
- Amendment No. 2 to Credit and Security Agreement dated September 28, 2017 (Filed With SEC on September 29, 2017)
- FOURTH AMENDMENT TO LICENSE AND CO-DEVELOPMENT AGREEMENT (Filed With SEC on August 10, 2017)
- Amended and Restated COMMERCIAL SUPPLY AGREEMENT BETWEEN CMC ICOS BIOLOGICS, INC. and APTEVO BIOTHERAPEUTICS LLC. DISCLAIMER THIS DOCUMENT IS ISSUED BY CMC FOR DISCUSSION PURPOSES... (Filed With SEC on August 10, 2017)
- APTEVO THERAPEUTICS INC. 2016 STOCK INCENTIVE PLAN (Filed With SEC on August 10, 2017)
- amendment No. 1 to CREDIT AND SECURITY AGREEMENT (Filed With SEC on May 12, 2017)
- THIRD AMENDMENT TO LICENSE AND CO-DEVELOPMENT AGREEMENT (Filed With SEC on December 15, 2016)
- TAX MATTERS AGREEMENT (Filed With SEC on August 2, 2016)
- CONTRIBUTION AGREEMENT (Filed With SEC on August 2, 2016)
- SEPARATION AND DISTRIBUTION AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF JULY 29, 2016 (Filed With SEC on August 2, 2016)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 2, 2016)
- NON-NEGOTIABLE PROMISSORY NOTE (Filed With SEC on August 2, 2016)
- TRANSITION SERVICES AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF JULY 29, 2016 TABLE OF CONTENTS (Filed With SEC on August 2, 2016)
- APTEVO THERAPEUTICS INC. CONVERTED EQUITY AWARDS INCENTIVE PLAN (Filed With SEC on August 2, 2016)
- EMPLOYEE MATTERS AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF JULY 29, 2016 TABLE OF CONTENTS (Filed With SEC on August 2, 2016)
- MANUFACTURING SERVICES AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF JULY 29, 2016 TABLE OF CONTENTS (Filed With SEC on August 2, 2016)
- CANADIAN DISTRIBUTOR AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF JULY 29, 2016 TABLE OF CONTENTS (Filed With SEC on August 2, 2016)
- TRADEMARK LICENSE AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF JULY 29, 2016 TRADEMARK LICENSE AGREEMENT (Filed With SEC on August 2, 2016)
- PRODUCT LICENSE AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF JULY 29, 2016 PRODUCT LICENSE AGREEMENT (Filed With SEC on August 2, 2016)
- APTEVO THERAPEUTICS INC. 2016 STOCK INCENTIVE PLAN (Filed With SEC on August 2, 2016)
- FORM OF INDEMNITY AGREEMENT (Filed With SEC on August 2, 2016)
- Ke to Aptevo Therapeutics Inc. Senior Management Severance Plan (Filed With SEC on August 2, 2016)